US biotech company ABG Lab has welcomed aesthetic doctor Dr Aamer Khan and its new global key opinion leader (KOL).
The company explains that Dr Khan will join other KOLs Dr Michael Kane and Professor Yana Yutskovskaya at a period of global growth for the brand.
ABG Lab contains mesotherapy treatments like Meso-Wharton P199 which triggers stem cell renewal of the skin, altering its structure and stimulating fibroblast synthesis of new collagen and elastin.
Dr Khan commented,
“Regenerative medicine in aesthetic treatments is the next big growth area in
our industry and has been at the heart of our practice since 2006. Having
practised and studied this subject extensively, I am very excited and honoured
to be partnering with such a progressive and forward-thinking brand like ABG
Lab which has launched an innovative and ground-breaking concept to the
injectable arena.”
